Potential Impacts

mAbLab invokes the true potential of monoclonal antibodies, pushing them to boundaries that traditional methods simply can't tap into. Using machine learning, we seek to revolutionize the space and give the world a fighting chance against pandemic disease.

Image from SepMag

Industry Level Impacts

On an industry level, mAbLab's method was associated with an 80% shorter lead time when it came to antibody development. This is uniquely important as it revitalizes stagnant development pipleines in the status quo and helps bridge the innovation deficit in pharmaceuticals. mAbLab also cuts down on the cost by completing replacing repetitive and error-prone in-vitro testing in favor of in silico methods that require simple computer softwares. By cutting costs and imporiving efficiency, mAbLab can subsidize costs for consumers, allowing for more people to enjoy the benefits of these new innovations.

Battling Future Pandemics

Monoclonal antibodies are a unique tool in curbing the spread of new diseases with complex etiologies. Their high specificity and minimal adverse effects make them a valid treatment against future pandemics. For COVID-19, mAb therapeutics were associated with a 39% lower risk for hospitalization or death after 28 days. mAbLab provides a more efficient framework for scientists to develop antibodies with specific functions in a significantly faster timeframe than status quo methods.

Chronic Disorders

Monoclonal antibodies also have a fighting chance against aggressive diseases like cancer and neurodegeneration. The FDA recently approved mAb therapeutics aducanumab and lecanemab, two products shown to tackle early onset Alzheimer's. With the customization that mAbLab provides, scientists can accurately combat the complex mechanisms behind such diseases without having to face the consequences of chemotherapy and other dangerous treatments.

Images from Left to Right: GoodRX Health. Business Insider, Illumina